Hepatitis News : Curing Hepatitis C Reduces Death From Any Cause
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis News » July 2011


emailprint

July 19, 2011

Curing Hepatitis C Reduces Death From Any Cause

People who have been treated for chronic hepatitis C virus (HCV) infection—and cured—are less likely to die from non-liver-related health problems, according to an article published in the June 2011 issue of Clinical Gastroenterology and Hepatology.

Using medical records from the U.S. Veterans Administration, Lisa Backus, MD, PhD, of the VA Medical Center in Palo Alto, California, and her colleagues looked at the impact of achieving sustained virologic responses (SVRs)—when no HCV is detectable, or in other words, when the person is cured, six months after completing treatment—on survival among 16,684 veterans with chronic hepatitis C. More than 90 percent were male, most were older than 50, and many of them had other serious illnesses, including heart disease, chronic obstructive pulmonary disease, diabetes, cirrhosis, hypertension and depression. Cigarette smoking, heavy drinking and hard drug use were common.

HCV genotypes 1, 2 and 3 were included in this analysis. The SVR rate was 35 percent for genotype 1, 72 percent for genotype 2 and 62 percent for genotype 3.

Patients were followed for nearly four years after finishing treatment.

Backus's group found that SVR lowered deaths from any cause across HCV genotypes. Having an SVR doubled five-year survival rates among people with HCV genotypes 1 and 2, and it tripled five-year survival rates among people with genotype 3.

The risk of death was greater for recent cigarette smokers, people with low platelets and people treated for a shorter duration. For genotypes 1 and 3, aging, diabetes, low albumin levels and an increased ratio of AST to ALT—both liver function tests—increased the risk of death, whereas in genotype 2, hypertension increased the risk of death.

As in this study, most people with HCV in the United States are older than 50 and are living with other medical conditions. The drop in death rates from any cause is an unexpected benefit from curing hepatitis C, especially because a recent study found that chronic hepatitis C doubles the risk of death from all causes.

This study underscores the importance of diagnosing and treating hepatitis C. HCV genotype 1 has become easier to cure with the approval of Incivek (telaprevir) and Victrelis (boceprevir). Adding one of these HCV protease inhibitors to pegylated interferon and ribavirin has boosted SVR rates to more than 70 percent, twice the rate in this study. The odds of a cure are also good for people with HCV genotypes 2 and 3; SVR rates range from 65 to 82 percent.

The authors concluded by suggesting that the benefits of SVR for people with hepatitis C and other medical conditions should overcome the reluctance to treat them, and that people with HCV should be encouraged to consider treatment, regardless of their genotype.

Search: hepatitis C, HCV, treatment, mortality, Incivek, Victrelis


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.